AGS Supports CMS Decision to Require Real-World Data for Monoclonal Antibodies
- . @AmerGeriatrics supports the recently announced decision from the Centers for Medicare and Medicaid Services (CMS) to require the collection of real-world information via a registry to study monoclonal antibodies. Read more: https://www.americangeriatrics.org/media-center/news/ags-supports-cms-decision-require-real-world-data-monoclonal-antibodies
New York (July 11, 2023) — The American Geriatrics Society (AGS) supports the recently announced decision from the Centers for Medicare and Medicaid Services (CMS) to require the collection of real-world information via a registry to study monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease. This decision applies to monoclonal antibodies that receive traditional approval from the Food and Drug Administration (FDA). Currently, lecanemab (trade name Leqembi™) is the only monoclonal antibody with this approval.